RIVIVE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rivive, and what generic alternatives are available?
Rivive is a drug marketed by Harm Reduction Therp and is included in one NDA. There are three patents protecting this drug.
This drug has fifty-three patent family members in thirty-seven countries.
The generic ingredient in RIVIVE is naloxone hydrochloride. There are twelve drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Rivive
A generic version of RIVIVE was approved as naloxone hydrochloride by HOSPIRA on September 24th, 1986.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RIVIVE?
- What are the global sales for RIVIVE?
- What is Average Wholesale Price for RIVIVE?
Summary for RIVIVE
| International Patents: | 53 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RIVIVE |
| What excipients (inactive ingredients) are in RIVIVE? | RIVIVE excipients list |
| DailyMed Link: | RIVIVE at DailyMed |
Pharmacology for RIVIVE
| Drug Class | Opioid Antagonist |
| Mechanism of Action | Opioid Antagonists |
US Patents and Regulatory Information for RIVIVE
RIVIVE is protected by three US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harm Reduction Therp | RIVIVE | naloxone hydrochloride | SPRAY, METERED;NASAL | 217722-001 | Jul 28, 2023 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Harm Reduction Therp | RIVIVE | naloxone hydrochloride | SPRAY, METERED;NASAL | 217722-001 | Jul 28, 2023 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Harm Reduction Therp | RIVIVE | naloxone hydrochloride | SPRAY, METERED;NASAL | 217722-001 | Jul 28, 2023 | OTC | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RIVIVE
See the table below for patents covering RIVIVE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 086391 | ⤷ Start Trial | |
| Austria | 16553 | ⤷ Start Trial | |
| Australia | 2012257785 | ⤷ Start Trial | |
| Australia | 2016204880 | ⤷ Start Trial | |
| Brazil | 112013029126 | ⤷ Start Trial | |
| Canada | 2835940 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RIVIVE
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1685839 | 92292 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch